Of the 2 patients with DLTs in cycle 1, patient 1 (who had CTCAE grade 3 increased ALT and CTCAE grade 3 increased AST in conjunction with CTCAE grade 2 hyperbilirubinemia in cycle 1) reported additional DLTs by the end of cycle 2 (CTCAE grade 3 increased ALT, CTCAE grade 3 increased AST, and CTCAE grade 2 hyperbilirubinemia); this patient required a second dose reduction of nintedanib (100 mg bid), as well as a dose reduction of docetaxel (60 mg/m2). The gene discussed is GPT; the disease is Hyperbilirubinemia.